天演药业（苏州）有限公司 ADAGENE
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) 2024-01-17 20:00
Adagene to Present at Investor and Scientific Conferences in September 2023-09-08 10:45
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels 2022-05-27 09:30
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab 2022-03-16 19:00
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2022-03-09 10:21
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates 2022-03-02 19:00
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences 2019-10-26 18:01
Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation 2019-03-04 13:06
Adagene Announces Collaboration for Discovery of Novel CAR-T with the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH) 2019-01-08 09:44
Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106 2018-11-01 08:00
US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lympoma Ph1 Trial 2018-07-10 08:08
Adagene Raises $50 Million in Series C Funding 2018-03-27 08:00
1